Under 10% of people eligible to benefit from GLP-1 drugs including Wegovy are able to get them, warns the WHO as it issues its initial recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidance affirms that obesity is a long-term condition that can be managed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key hurdles to broad availability to the jabs that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Scarcity
Even under the current most favorable outlook, the production of such drugs could only cover about 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation calls on countries and companies to widen availability, via approaches like patent sharing.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Work
The injections replicate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people reduce food intake.
Patients usually start to lose weight in the initial weeks of commencing the regular doses.
Research indicates people may regain a significant portion within a year of stopping the medication, as their normal appetite return.
Being above a healthy weight raises your chance for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the WHO.
